---
title: "Weekly Recap | CSPC PHARMA -2.22%, most brokers rate it buy"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/306349979.md"
description: "CSPC Pharma fell 2.22% to close at HK$7.92 for the week, while the Hang Seng Index lost 5.65%, putting the stock about 3.43 percentage points ahead of the benchmark. Trading only ran for four days, with a 9.4% weekly amplitude. The pattern was a pullback, a rally, then a fade: Monday dipped to 7.77, Tuesday marked the week’s low at 7.60 before recovering, Wednesday spiked to 8.355 on volume of 129.4m shares, and Thursday settled back at 7.92."
datetime: "2026-11-21T05:07:43.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/306349979.md)
  - [en](https://longbridge.com/en/news/306349979.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/306349979.md)
generator: "portal-rs"
---

# Weekly Recap | CSPC PHARMA -2.22%, most brokers rate it buy

## The Week

CSPC Pharma (1093.HK) fell 2.22% to close at HK$7.92 for the week, while the Hang Seng Index lost 5.65%, putting the stock about 3.43 percentage points ahead of the benchmark. Trading only ran for four days, with a 9.4% weekly amplitude. The pattern was a pullback, a rally, then a fade: Monday dipped to 7.77, Tuesday marked the week’s low at 7.60 before recovering, Wednesday spiked to 8.355 on volume of 129.4m shares, and Thursday settled back at 7.92. Wednesday’s volume was well above the week’s daily average of 88.7m shares, showing the up-move carried heavier turnover.

## Key Events

The main thread was nine-month results plus licensing milestones. On 18 November, before the open, the company reported unaudited nine-month figures to 30 September 2026: net profit of RMB7.076b, up 101.5% year on year, with revenue up 27% and a gross margin of 73.6%. AstraZeneca licence income and finished-drug growth were the main contributors. Earlier in the week, on 16 November, CSPC announced it had initiated the first centre in China for a Phase Ib/II trial of SYH2051 in combination with irinotecan liposome for advanced solid tumours. Then after the close on 19 November, the company disclosed receipt of a US$15m development milestone payment from Corbus Pharmaceuticals under the exclusive licence agreement for CRB-701 (SYS6002). On the industry side, Citi noted on 19 November that drugmakers described the 2026 NRDL price cuts as mild and manageable.

## Analyst Ratings

Coverage totals 24 institutions: 17 rate it buy, 4 rate it overweight, 1 hold, 1 underweight and 1 sell. The consensus rating is buy, with a consensus target of HK$12.57, about 58.7% above the latest close of HK$7.92. The target range runs from HK$8.00 to HK$19.00, a wide spread that shows meaningful disagreement on valuation. The stock ranks first within the pharma industry out of 29 names covered. Several brokers updated views on 19-20 November: Citi lifted its target to HK$15, Goldman Sachs to HK$12.83, Morgan Stanley said third-quarter finished drug sales slightly beat expectations, and CICC called results in line with a solid core business.

## The Week Ahead

No company-specific earnings or clinical readouts are scheduled for next week. The next confirmed event is the full-year 2026 results on 25 March 2027, before market open, where consensus sits at EPS of 0.8745 and revenue of RMB38.7b, implying year-on-year growth of 80.77% and 24.27% respectively. Nearer term, investors will watch the durability of licence income and finished-drug growth, the enrolment progress of the SYH2051 combination trial, and any further read-through from the NRDL pricing update.

## In Short

CSPC’s own news flow leaned positive this week: nine-month profit doubled, two licensing milestones landed, and most brokers rate it buy with a consensus target about 58.7% above spot. Yet the stock still lost 2.22%, though it held up much better than the Hang Seng Index, outperforming by roughly 3.43 percentage points. Valuation is mild at 10.52x P/E and 2.11x P/B. On the latest trading day, large-lot money was tilted towards net buying while small-lot money was tilted towards net selling. The question ahead is whether licence income recognition and finished-drug growth keep delivering, and whether broad Hong Kong market pressure continues to drag on the stock.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [01093.HK](https://longbridge.com/en/quote/01093.HK.md)

## Related News & Research

- [CSPC Pharmaceutical Group: Revenue, licensing income and pipeline milestones advanced alongside a 73.6% 1-9M gross margin](https://longbridge.com/en/news/305926514.md)
- [CSPC Starts Phase I/II Trial of SYS6055 for B-Cell Non-Hodgkin Lymphoma in China](https://longbridge.com/en/news/304626206.md)
- [Concerns Surrounding Srinibas Pradhan Constructions' (NSE:SPCON) Performance](https://longbridge.com/en/news/306347727.md)
- [PancakeSwap to Host Meetup in Bangkok on November 29th](https://longbridge.com/en/news/306350614.md)
- [Dutch court bars EU sales of BYD Ti7, citing infringement of Land Rover Defender design rights](https://longbridge.com/en/news/306379119.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**